Does concomitant diabetes affect treatment responses in overactive bladder patients?

Area of Science:

• Pharmacology
• Urology
• Endocrinology

Background:

• Overactive bladder (OAB) is a common condition affecting quality of life.
• Diabetes mellitus is a prevalent comorbidity that may influence OAB treatment outcomes.
• Muscarinic receptor antagonists are a mainstay in OAB pharmacotherapy.

Purpose of the Study:

• To compare the efficacy and tolerability of darifenacin in OAB patients with and without diabetes.
• To investigate the impact of diabetes on treatment response to darifenacin.

Main Methods:

• Post hoc analysis of a large, non-interventional study.
• Inclusion of 532 diabetic and 1315 non-diabetic OAB patients treated with darifenacin.
• Evaluation of treatment responses using multiple regression models.

Main Results:

• Diabetic patients had differing baseline characteristics but similar OAB symptom severity and starting darifenacin doses compared to controls.
• Diabetes was associated with a small, statistically significant reduction in OAB symptom improvement.
• No significant differences in treatment tolerability were observed between diabetic and non-diabetic groups.

Conclusions:

• Darifenacin demonstrates comparable efficacy in reducing OAB symptoms for patients with and without diabetes.
• Tolerability of darifenacin is not significantly affected by the presence of diabetes.
• Muscarinic receptor antagonists can be considered for OAB management in patients with diabetes.